NLRP3 and Parkinson disease: Given that microglial activation and NLRP3 inflammasome-mediated neuroinflammation are critical pathological mechanisms in Parkinson’s disease (PD), we employed an in vivo model involving stereotactic injection of LPS into the substantia nigra to induce PD-like pathology (Figure 5A).